Kymera Trials IRF5 And STAT6 Degraders As Market Weighs Long Term Upside [Yahoo! Finance]
Kymera Therapeutics, Inc. (KYMR)
Company Research
Source: Yahoo! Finance
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Kymera Therapeutics has begun first in human clinical trials of an IRF5 directed therapy, a new approach to targeting immune driven disease. The company has also advanced KT-621, its lead oral STAT6 degrader, with early data suggesting potential to rival or surpass a key existing therapy. These milestones highlight progress in Kymera Therapeutics' immunology pipeline at a time when interest in protein degradation platforms remains high. Kymera Therapeutics (NasdaqGM:KYMR) is drawing attention with these pipeline updates, backed by a current share price of $79.03 and a 1 year return of 129.9%. Over 3 years the stock shows a return of 154.6%, while over 5 years it shows 77.0%. This gives investors context for how the market has viewed the story over different time frames. The new IRF5 trial and KT-621 progr
Show less
Read more
Impact Snapshot
Event Time:
KYMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYMR alerts
High impacting Kymera Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYMR
News
- Kymera Therapeutics (KYMR) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.MarketBeat
- Kymera Therapeutics, Inc. (KYMR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual MeetingGlobeNewswire
- Kymera CEO Nello Mainolfi's Boldest Line Had Nothing to Do With the Earnings Miss [Yahoo! Finance]Yahoo! Finance
KYMR
Earnings
- 2/26/26 - Miss
KYMR
Sec Filings
- 3/11/26 - Form 4
- 3/11/26 - Form 144
- 3/4/26 - Form 4
- KYMR's page on the SEC website